Ian Michael Estepan
Net Worth
Last updated:
What is Ian Michael Estepan net worth?
The estimated net worth of Mr. Ian Michael Estepan is at least $2,332,311 as of 30 Aug 2024. He owns shares worth $672,131 as insider, has earned $976,060 from insider trading and has received compensation worth at least $684,120 in Sarepta Therapeutics, Inc..
What is the salary of Ian Michael Estepan?
Mr. Ian Michael Estepan salary is $684,120 per year as Executive Vice President & Chief Financial Officer in Sarepta Therapeutics, Inc..
How old is Ian Michael Estepan?
Mr. Ian Michael Estepan is 49 years old, born in 1976.
What stocks does Ian Michael Estepan currently own?
As insider, Mr. Ian Michael Estepan owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | Executive Vice President & Chief Financial Officer | 33,946 | $19.8 | $672,131 |
What does Sarepta Therapeutics, Inc. do?
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Ian Michael Estepan insider trading
Sarepta Therapeutics, Inc.
Mr. Ian Michael Estepan has made 2 insider trades in 2024, according to the Form 4 filled with the SEC. Most recently he sold 5,985 units of SRPT stock worth $822,100 on 30 Aug 2024.
The largest trade he's ever made was exercising 6,250 units of SRPT stock on 21 Jun 2024. As of 30 Aug 2024 he still owns at least 33,946 units of SRPT stock.
Sarepta Therapeutics key executives
Sarepta Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Gilmore O'Neill M.D. (60) Executive Officer
- Dr. Louise Rodino-Klapac Ph.D. (47) Chief Scientific Officer and Head of R&D
- Mr. Douglas S. Ingram (62) Pres, Chief Executive Officer & Director
- Mr. Ian Michael Estepan (49) Executive Vice President & Chief Financial Officer
- Mr. Joseph Bratica (61) Controller & Vice President
- Mr. William F. Ciambrone (61) Executive Vice President of Technical Operations